Vaccines

The submission comes day after BNT162b2 became the first fully approved COVID-19 vaccine by the FDA.

David Weber, MD, MPH, explains what portion of the population may buy into the newly approved Pfizer-BioNTech vaccine.

The full approval for BNT162b2 will afford physicians greater prescribing capability, and will likely drive workplace vaccine mandates.

The Biden administration reportedly hopes for FDA-authorized booster doses for the adult general population in the next month.

The US is targeting a possible Fall rollout of publicly available doses, yet experts debate their current necessity.

An England study shows the Pfizer-BioNTech and AstraZeneca vaccines remain effective in reducing symptomatic disease risk.

Emergency authorization may be complete before the end of August, ensuring more protection for patients burdened with certain chronic diseases.

The report of promising phase 2 findings align with word that an FDA submission will be delayed until later this year.

Last influenza season was notably quiet during peaking COVID-19 cases. Experts explain what may influence risk of dueling epidemics this year.

The prophylaxis showed non-inferiority across shared serotypes with an available 13-valent vaccine in its indication-supporting data.

The designation moves the companies' PDUFA date up to January 2022, when BNT162b2 may become the first regulated COVID-19 vaccine.

The announcement aligns with an FDA and CDC statement against the need for booster doses.

Experts suggest the vaccine, if regulated by the FDA, would benefit the US as a booster dose to combat waning immunity against emerging variants.

The newest data for the real-world assessment show the mRNA vaccine provides greater immunogenicity in persons aged 12-15 years old than in young adults.

TAK-003, from Takeda, is showing slightly improved protection among seropositive participants through its 36-month follow-up.

A concerted effort to increase flu vaccination during the COVID-19 pandemic resulted in more protection among a high-risk population, as well as educational opportunities for pharmacy students.

Discriminately affected populations face a wall of hurdles, historic and contextual, in buying into COVID-19 vaccine benefit. What can clinicians and public health officials do to help?

The first US COVID-19 vaccine breaks ground again, as the first authorized for patients as young as 12 years old.

New real-world research suggest the vaccine may help provide control of the pandemic virus.

A treatment arm of up to 3000 participants aged 12-17 years old will be rolled into the North American-based PREVENT-19 trial.

New analysis of registry data suggest pregnant persons are not facing particularly worse pregnancy nor neonatal outcomes after mRNA vaccination.

An interventional cardiologist discusses the observed cases of cerebral venous thrombosis in women administered the Johnson & Johnson COVID-19 vaccine.

Carlos del Rio, MD, discusses the United States' pandemic situation in assessing the blood clot events observed in 6 Johnson & Johnson vaccine recipients.

Jason Gallagher, PharmD, adds context behind the FDA and CDC's decision to pause and review blood clotting events in 6 women given the company's COVID-19 vaccine.

The federal agencies will advise states withhold administration of the Johnson & Johnson one-shot product while investigating risk of a rare blood clot disorder.

Our editor-in-chief writes on the role caregivers play in informing the public on the perks of a more vaccinated population.

The newest research of rare adverse events among patients administered the vaccine highlights that venous or arterial thrombosis can develop in unexpected regions, including the brain or abdomen, 5-20 days after administration.

A new commentary from experts highlight the evolving understanding of antibody response in vaccinated transplant patients.

An expert stresses the need to consider individuals' worry over information—and even their history with systemic biases.